BILe Acid-gut Microbiome Axis MODification Through Diet Education for Colorectal Cancer Prevention

Recruiting now · Not applicable

Conditions studied: Colorectal Cancer Prevention, Colorectal Adenoma

In brief

This research study is a prospective, single-arm clinical trial to assess the effect of a dietary intervention for more plant-based and less animal-based food intake on secondary bile acid production, gut microbiota, circulating biomarkers and gene expression associated with colonic bile acid receptor activation and colorectal cancer.

Key facts

Study ID

NCT07162337

Run by

Massachusetts General Hospital

People needed

40

Starts

2026-06-18

Expected to finish

2028-06-01

Last updated by the study team

2026-06-23

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Underwent screening or surveillance colonoscopy with removal of at least one adenoma.
• Age 18-80 years.
• Habitually consume a Western pattern diet.
• BMI of at least 18.5 kg/m2 but less than 35 kg/m2
• Weight stable in last 3 months (loss or gain <4%).
• Subjects must be able and willing to follow study procedures and instructions.
• Ability to understand and the willingness to sign a written informed consent document.

You may not qualify if…

• Strict dietary patterns (e.g., vegan, carnivore, kosher, low-carb etc.).
• Diagnosis of inflammatory bowel disease, liver or kidney disease, bleeding diathesis.
• Any prior diagnosis of gastrointestinal cancer (including esophageal, small intestine, colon, pancreatic), or any diagnosis of other cancers (with the exception of nonmelanoma skin) in which there has been any active treatment within the last three years.
• Known diagnosis of Familial Adenomatous Polyposis (FAP) or Hereditary Non-Polyposis Colorectal Cancer (HNPCC, Lynch Syndrome).
• Any adenoma that was not completely removed during previous colonoscopy.
• Known bleeding tendency/condition (e.g. von Willebrand disease) or history of peptic ulcer or gastrointestinal bleed requiring hospitalization, endoscopic complications, or contraindication to colonoscopy.
• Current use of anticoagulant therapies, including Heparin, Warfarin, Dalteparin sodium, Bivalirudin, Argatroban, Lepirudin, Heparin Sodium, Heparin/Dextrose, and an unwillingness or inability to discontinue anticoagulants.
• Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
• Regular use of aspirin.
• Use of antibiotics or probiotics.
• Inability or unwillingness to abstain from limited consumption of animal-based food or to provide blood or stool samples during the study.
• Participants who are receiving any other investigational agents.
• Pregnant or breastfeeding.
• Known positive test for human immunodeficiency virus (HIV), hepatitis C virus, or acute or chronic hepatitis B infection.

Where it is running

• Massachusetts General Hospital Cancer Center — Boston, Massachusetts, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.